ESPR
Esperion Therapeutics, Inc.
Key Financials
Revenue
$403.1M
↑ 21.3%
Operating Income
$60.3M
↑ 10.8%
Net Income
$-22682000
↑ 56.2%
Shareholders' Equity
$-301965000.00
↑ 22.3%
Total Assets
$465.9M
↑ 35.5%
Total Liabilities
$767.9M
↑ 4.8%
EPS (Diluted)
$-0.11
↑ 60.7%
Cash & Equivalents
$167.9M
↑ 16.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G | 8/13/2026 | View on SEC |
| SCHEDULE 13G | 7/31/2026 | View on SEC |
| 15-12G | 7/23/2026 | View on SEC |
| EFFECT | 7/15/2026 | View on SEC |
| EFFECT | 7/15/2026 | View on SEC |
| EFFECT | 7/15/2026 | View on SEC |
| EFFECT | 7/15/2026 | View on SEC |
| EFFECT | 7/15/2026 | View on SEC |
| EFFECT | 7/15/2026 | View on SEC |
| SCHEDULE 13G/A | 7/14/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ESPR |
| Company Name | Esperion Therapeutics, Inc. |
| CIK | 1434868 |
| Sector | Pharmaceutical Preparations |
| Industry | Accelerated filer Smaller reporting company |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 734-887-3903 |